Valuation
- Market cap
- 119,082,000
- Revenue TTM
- $19,090,000
- Net income TTM
- $-82,130,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -430.23%
- Debt to equity
- 0.00
Trading
- Volume
- 1,126,900
- Avg volume
- 770,900
- Day's range
- $3.51 – $3.84
- Shares out
- 31,420,000
- Stochastic %K
- 11%
- Beta
- 0.64
- Analysts
- Strong Sell
- Price target
- $22.00
Company profile
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was...
Show more
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 925 7000
- Website
- https://www.lenz-tx.com
- Address
- 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States
Latest news
No headlines yet.
